Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.

In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR4 or deeper, corresponding to BCR-ABL1 ≤ 0.01% on the International Scale (IS)) is considered as a prognostic factor for treatment free remission in stopping trials. MR level determination i...

Full description

Bibliographic Details
Main Authors: Birgit Spiess, Sébastien Rinaldetti, Nicole Naumann, Norbert Galuschek, Ute Kossak-Roth, Patrick Wuchter, Irina Tarnopolscaia, Diana Rose, Astghik Voskanyan, Alice Fabarius, Wolf-Karsten Hofmann, Susanne Saußele, Wolfgang Seifarth
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0214305

Internet

https://doi.org/10.1371/journal.pone.0214305

Similar Items